Thalidomide is an immunomodulatory drug and primarily prescribed as a sedative and hypnotic. Treatment with thalidomide inhibited osteoblast development. Bone sialoprotein (BSP) is a mineralized tissue-specific protein that appears to function in the initial mineralization of bone. BSP expression is essentially restricted to differentiated cells of mineralized connective tissues and that the expression of BSP is developmentally regulated. To determine molecular mechanisms involved in the suppression of bone formation we have analyzed the effects of thalidomide on BSP gene expression.
Introduction
Thalidomide was sold as a sedative and was prescribed to pregnant woman as a treatment for morning sickness. Use of thalidomide during weeks 3 to 8 of gestation causes multiple birth defects such as limb, ear, cardiac and gastrointestinal malformations. Thalidomide is potent immunomodulators with biologic effects on both cytokine stimulation and cell-mediated immunity (1, 2) . Thalidomide enhances degradation of tumor necrosis factor-α (TNF-α) mRNA, thus suppressing this proinflammatory cytokine release from endotoxin-stimulated monocytes and macrophages (3) . Previous studies have suggested thalidomideinduced oxidative stress and its antiangiogenic action as a possible cause of teratogenicity (4, 5) . Recently, thalidomide is used in the treatment of leprosy and multiple myeloma, although it causes teratogenicity. If thalidomide is used under strict control and removal of its side effects is desirable for wide applications of this potentially useful drug (6) . Cereblon (CRBN) was identified as a thalidomidebinding protein, which forms an E3 ubiquitin ligase complex with damaged DNA binding protein 1 (DDB1) and Cul4A that is important for limb out growth and expression of the fibroblast growth factor 8 (FGF8) in zebrafish and chicks.
Thalidomide initiates its teratogenic effects by binding to CRBN and inhibiting the associated ubiquitin ligase activity (7) . Treatment with thalidomide and thalidomide derivatives with immunomodulatory functions such as lenalidomide or pomalidomide significantly inhibited osteoblast development in vitro, as reflected by a reduction of alkaline phosphatase activity and matrix mineralization (8) .
Bone sialoprotein (BSP) is a sulfated and phosphorylated glycoprotein found almost exclusively in mineralized tissues (9, 10) . The temporo-spatial deposition of BSP into the extracellular matrix of bone (11, 12) and the ability of BSP to nucleate hydroxyapatite crystal formation (13) indicate a potential role for BSP in the initial mineralization of bone. BSP is also expressed in several pathologies in which mineralization occurs including malignant breast cancer where it is associated with the formation of ectopic hydroxyapatite microcrystals (14) (15) (16) . Thus, regulation of BSP gene transcription appears to be important in the differentiation of osteoblasts, for bone matrix mineralization and for pathologic mineralization. To study the transcriptional regulation of BSP gene expression, we and other groups have cloned and sequenced the rat, human and mouse BSP gene promoters (17) (18) (19) , which are highly conserved within a 370 bp proximal region. This region includes an inverted TATA box (20) overlapping a vitamin D response element (21) and an inverted CCAAT box (−50 to −46), which is required for basal transcriptional activity (22, 23) . In addition, a fibroblast growth factor 2 (FGF2) response element (FRE; −92 to −85)(24), a pituitary-specific transcription factor-1 (Pit-1) motif (−111 to −105), that mediates the stimulatory effects of parathyroid hormone (25) , and a homeodomain protein-binding site (HOX; −199 to −192) (26) , have been characterized.
Further upstream in the rat promoter a transforming growth factor-β activation element (−499 to −485) (27) and a glucocorticoid response element (−920 to −906), overlapping an AP1 site (−921 to −915) (10, 28) has also been identified.
To elucidate molecular pathways through which thalidomide suppresses bone formation we have analyzed the effects of thalidomide on BSP gene expression in ROS 17/2.8 cells. These studies show that thalidomide exerts suppresses transcription of the BSP gene through an inverted CCAAT and a CRE in the rat BSP gene promoter.
Materials and Methods

Materials
Cell culture media, fetal calf serum (FCS), Lipofectamine, penicillin and streptomycin, trypsin were obtained from Invitrogen (Carlsbad, CA, USA). The pGL3-promoter vector and pSV-ß-Galactosidase (ß-Gal) control vector were purchased from Promega (Madison, WI, USA). Thalidomide was from Sigma (St. Louis, USA). All chemicals used were of an analytical grade.
Cell culture
The rat clonal cell line, ROS 17/2.8 (generously provided by Dr. Jaro Sodek) was used in these studies as an osteoblastic cell line that synthesizes BSP (10, 29) . Cells grown to confluence in 60 mm tissue culture dishes in α-MEM medium containing 10% FCS were changed to α-MEM without serum and incubated with or without 10 μg/ml thalidomide for time periods extending over 3-24 h to determine the effects of thalidomide on the expression of BSP mRNA. RNA was isolated from triplicate cultures at various time intervals and analyzed for the expression of BSP mRNA by Northern hybridization as described below.
Northern hybridization
Total RNA from the ROS 17/2.8 was extracted with guanidium thiocyanate and, following purification, 20 μg aliquots of RNA were fractionated on 1.2% agarose gel and transferred onto a Hybond XL membrane, as described previously (27) . Hybridizations were performed at 42℃ with Antibodies were added to each reaction mixture and incubated for 4 h at 4℃ before electrophoresis was performed under the same conditions as described above.
Statistical analysis
Triplicate samples were analyzed for each experiment, which was replicated at least three times to ensure consistency of the responses to thalidomide. Significant differences between control and treatment were determined using the oneway ANOVA. 1A) . Thus, 10 μg/ml of thalidomide was used to determine a time course of BSP mRNA expression (Fig.   1B ). Thalidomide suppressed BSP mRNA levels at 12 h.
Results
Suppression
Osteopontin mRNA levels were decreased slightly at 3, 6
and 12 h (Fig. 1B) , whereas no effect on GAPDH mRNA was observed (Fig. 1A and B) . (Fig. 3) . To more closely define the regulatory element between nts −116 and −43 that is utilized by thalidomide, we prepared a series of 5ʼ deletion constructs. −60BSPLUC, −84BSPLUC and −108BSPLUC constructs suppressed by thalidomide (Fig. 4) . The results showed that the element responding to thalidomide was present between nts −84 and the transcription start site in the BSP promoter ( Fig. 3   and 4) . Next, we introduced 2-base pair mutations in the pLUC3 construct. Whereas mutations in the FRE and Pit-1 had no effect on thalidomide, mutations of the CCAAT and CRE significantly reduced the thalidomide effects on the transcriptional activity (Fig. 5) .
Gel Mobility Shift Assays
To clarify nuclear proteins that bind to the inverted CCAAT and CRE and mediate the thalidomide effects on transcription, double-stranded oligonucleotides were end- (Fig. 6, lanes 1-4) . After thalidomide stimulation for 3 h, CRE-protein complex formation was increased, decreased at 6 h and increased again at 12 h (Fig. 6 , lanes
5-8). On the other hand, FRE-and Pit-1-protein complexes
formations did not change (Fig. 6, lanes 9-16) . That the DNA-protein complex represents a specific interaction was indicated by competition experiments in which 40-fold excess of CRE reduced the amount of complex formed (Fig.   7, lane 3) . In contrast, 40-fold excess mCRE did not compete with complex formation (Fig. 7, lane 4) . CRE-binding protein was supershifted by phospho-CREB1 antibody (Fig.   7 , lane 7), and disrupted by CREB1, c-Fos, c-Jun, JunD and CREB2 antibodies (Fig. 7, lanes 6, 8, 9 , 11, 12)
Discussion
In this study we show that thalidomide suppresses the after the administration of 10 μg/ml thalidomide to ROS17/2.8 cells. Total RNA was isolated from triplicate cultures harvested after incubation times of 3, 6 and 12 h, and used for Northern hybridization analysis using a 32 Plabelled rat BSP DNA probe and a GAPDH DNA probe. The hybridized bands, representing the two polyadenylated forms (1.6-kb and 2.0-kb) of rat BSP mRNA, were scanned in a Bio-imaging analyzer. That the CRE mediates the effects of thalidomide on BSP was initially determined by transient transfection assays in which promoter constructs spanning the proximal promoter Fig. 6 Gel mobility shift assays using inverted CCAAT, CRE, FRE and Pit-1. After stimulation by 10 μg/ml thalidomide (3, 6 and 12 h), CRE-protein complexes were increased at 3 h, decreased at 6 h and increased again at 12 h (lanes 5-8). CCAAT-, FRE-and Pit-1-protein complexes did not change after stimulation by thalidomide (lanes 1-4, 9-12, 13-16). DNA-protein complexes were separated in a 5% polyacrylamide gel with a low-ionic-strength Tris-borate buffer, dried under a vacuum, and exposed to an imaging plate for quantitation using an imaging analyzer.
(−84 and −43; Fig. 4 ) of the BSP gene were used. This region encompasses an inverted CCAAT box (nts −50 and −46), a CRE (nts −75 and −68) and a putative Runx2 (nts −84 and −79) (Fig. 3) . Mutation of the inverted CCAAT and CRE was used to demonstrate that the effects of thalidomide could be blocked in the absence of CCAAT and CRE (Fig. 5) . Thus, to further establish the site of BSP gene regulation, gel mobility shifts were used to identify proteins in nuclear extracts of ROS 17/2.8 cells that selectively bound to the CRE and inverted CCAAT sequences (Fig. 6 ).
CRE-binding proteins were increased at 3 h, decreased at 6 h and increased again at 12 h (Fig. 6, lanes 5-8) . In contrast, the protein binding to the inverted CCAAT did not change after stimulation with thalidomide as previously In this study, therefore, we have shown that thalidomide suppresses BSP expression via inverted CCAAT and CRE elements, which is conserved in mammalian promoters of were added separately to each reaction. DNA-protein complexes were separated on 5% polyacrylamide gel in low-ionic-strength Tris-borate buffer, dried under a vacuum, and exposed to an imaging plate for quantitation using an imaging analyzer.
